• OncologyTube
    • 0
      • Title
        User LIVE NOW
      • Logo LIVE NOW
        Title
        User
      • Schedule An Interview
        • Schedule A Remote Interview with OncologyTube
    • Home
    • Trending

    • Sign In

    • Audios and Videos
    • Videos
    • Audios

    • Channels

    • Browse Channels

    • Categories

    • Acute Lymphoblastic Leukemia 5648
    • Acute Myelogenous Leukemia 202
    • Bladder Cancer 71
    • Bone Metastases 2
    • Brain Cancer 59
    • Breast Cancer 233
    • Business Management 3
    • Cervical Cancer 6
    • Chronic Lymphocytic Leukemia 192
    • Chronic Myelogenous Leukemia 43
    • Colorectal Cancer 110
    • COVID-19 27
    • Gastrointestinal Cancer 93
    • General 320
    • Head and Neck Cancers 74
    • Hematologic Malignancies 180
    • Hodgkin Lymphoma 28
    • Immunotherapy 155
    • Kidney Cancer 376
    • Liver Cancer 25
    • Lymphoma 180
    • Melanoma and Skin Cancer 57
    • Multiple Myeloma 466
    • Myeloproliferative Disease 20
    • News 148
    • Non-Hodgkin Lymphoma 77
    • Non-Small Cell Lung Cancer 413
    • Other 256
    • Ovarian Cancer 43
    • Pancreatic Cancer 73
    • Patient Resources 28
    • Pediatric Cancer 3
    • Prostate Cancer 225
    • Sickle Cell 21
    • Small Cell Lung Cancer 72
    • Soft Tissue Sarcoma 10
    • Supportive Care 47
    • Testicular Cancer 3
    • Urology 14
    • Uterine Cancer 7

    • About
    • Contact
    Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research 5-Year Update of the ECHELON-1 Study Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research 5-Year Update of the ECHELON-1 Study
    00:09:38

    Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research 5-Year Update of the ECHELON-1 Study

    Radhakrishnan Ramchandren, MD Investigator and Chief, Division of Hematology/Oncology from the University of Tennessee Medical Center discusses the ASH 2020 abstract - 2973 Brentuximab Vedotin with Chemotherapy for Patients with Previously Untreated, Stage III/IV Classical Hodgkin Lymphoma: 5-Year Update of the ECHELON-1 Study.


    Introducing
    Historically, almost all classical Hodgkin lymphoma (cHL) relapses occur during the first 5 years (Radford et al, BMJ 1997). In phase 3 ECHELON-1 trial (NCT01712490), treatment with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (A+AVD) significantly improved modified progression-free survival (PFS) compared to doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) in patients (pts) with newly diagnosed Stage III/IV cHL (Connors et al, NEJM 2018). In the intent-to-treat (ITT) population, which was consistent across most main pt subgroups, regardless of the status of the interim positron emission tomography (PET) scan, disease level, and baseline disease risk factor score, 3- and 4-year follow-up (Straus et al, Blood 2020; Bartlett et al, Blood 2019) recorded durable PFS gain with A+AVD vs ABVD. After a median follow-up of 55.6 months, we announce revised efficacy and safety outcomes for pts in the ECHELON-1 trial.


    Methodology
    An exploratory study of PFS (time from randomization to relapse, progression, or death from any cause) per investigator (INV) was performed in this longer follow-up assessment, with a cutoff date of May 18, 2020. To obtain up to six cycles of A+AVD (n=664) or ABVD (n=670) intravenously on days 1 and 15 of the 28-day period, pts with previously untreated Stage III or IV cHL were randomized to 1:1. A post-cycle 2 (PET2) interim PET scan was required. During the extended follow-up period, resolution and progress (defined as an improvement by ⁇ 1 grade from the worst grade as of the latest assessment) of peripheral neuropathy (PN) in pts with continuing symptoms at the end of treatment (EoT) was monitored. It also examined the prevalence of secondary malignancies and the occurrence and outcomes of pregnancies among pts and their partners.



    Outcomes
    The approximate 5-year PFS rates with extended follow-up (median 55.6 months; 95 percent CI 55.2-56.7) were 82.0 percent (95 percent CI 78.7-84.8) for A+AVD and 75.2 percent (95 percent CI 71.5-78.4) for ABVD. Overall, A+AVD over ABVD was preferred by PFS per INV (HR 0.691; 95 percent CI 0.543–0.880; p=0003) (Table). PET2 status and age exploratory subgroup analysis showed PFS benefits irrespective of PET2 status (Table); A+AVD vs. ABVD median 5-year PFS per INV in the ITT population was 84.7 percent vs. 78.8 percent in PET2-negative pts (HR 0.676; 95 percent CI 0.512–0.892; p=0.005) and 60.6 percent vs. 45.9 percent in PET2-positive pts (HR 0.703; 95 percent CI 0.393–1.256; p=0.230). The advantage of PFS with A+AVD over ABVD was also independent of the number of risk factors from the International Prognostic Factors Project (IPFP) (Figure). 84 percent (370/442) and 86 percent (245/286) of pts with treatment-emergent PN reported full resolution or improvement of symptoms in the A+AVD and ABVD arms, respectively, after a median follow-up of nearly 5 years. The median period for full resolution of ongoing EoT PN events was 30 weeks (range 0-262) in the A+AVD arm and 16 weeks (range 0-267) in the ABVD arm; the median time for change was 49 weeks (range 8-270) and 12 weeks (range 2-70). Of the 132 (30 percent) pts in the A+AVD arm with continuing PN, 77 (17 percent), 39 (9 percent), 15 (3 percent), and 1 (<1 percent) witnessed maximum grade 1, 2, 3, or 4 severity, respectively. PN was continuous at 61 pts (21 percent) in the ABVD arm; overall intensity was grade 1, 2, 3, or 4 at 40 (14 percent), 17 (6 percent), 4 (1 percent), and 0 pts, respectively. A total of 124 pregnancies (40 female and 30 male pts in the A+AVD arm; 26 female and 28 male pts in the ABVD arm) were recorded among the pts and their partners. The proportion of live births was comparable between female pts (26/40 in the A+AVD arm and 17/26 in the ABVD arm, 65% in each arm) and male pts (19/30 [63%] in the A+AVD arm and 20/28 [71%] in the ABVD arm). There were no stillbirths registered. Additional follow-up will be provided at an average median of ~5 years and secondary data on malignancy.



    Findings
    A+AVD continues to show a robust and enduring treatment advantage independent of disease level, risk factor score, and PET2 status after a median follow-up of 55.6 months. In addition, treatment adaptation to interim PET2 status is not needed in comparison with ABVD, and exposure to bleomycin is avoided. The sustained advantage of PFS with A+AVD is combined with a manageable safety profile in both treatment arms, with symptoms of PN improving or resolving with time and comparable pregnancy rates. The advantages observed with A+AVD at this significant milestone indicate that A+AVD is an attractive treatment choice for all pts with Stage III or IV cHL previously untreated.

    18 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login

    Suggested

    Trending

    Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma
    00:19:35

    Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma

    Free
    307 Views
    2 years ago
    MediComOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Promising therapeutic developments for Hodgkin lymphoma
    00:02:59

    Promising therapeutic developments for Hodgkin lymphoma

    Free
    149 Views
    2 years ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    MRD in lymphoma
    00:02:29

    MRD in lymphoma

    Free
    183 Views
    2 years ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    CAR T-cell therapy in B-cell malignancies
    00:02:18

    CAR T-cell therapy in B-cell malignancies

    Free
    273 Views
    2 years ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3
    • 4
    • 5
    • 6
    • 7

    Hodgkin Lymphoma

    Alex F. Herrera, MD @cityofhope #ASH20 # HodgkinLymphoma #cancer #research 472 Consolidation with Nivolumab and Brentuximab Vedotin Alex F. Herrera, MD @cityofhope #ASH20 # HodgkinLymphoma #cancer #research 472 Consolidation with Nivolumab and Brentuximab Vedotin
    00:07:38

    Alex F. Herrera, MD @cityofhope #ASH20 # HodgkinLymphoma #cancer #research 472 Consolidation with Nivolumab and Brentuximab Vedotin

    Free
    11 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research 5-Year Update of the ECHELON-1 Study Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research 5-Year Update of the ECHELON-1 Study
    00:09:38

    Radhakrishnan Ramchandren, MD @utmedicalcente #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research 5-Year Update of the ECHELON-1 Study

    Free
    18 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Miles Prince, MD @MilesPrince4 @PeterMacCC #ASH20 #HodgkinsLymphoma #Cancer #Research The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study Miles Prince, MD @MilesPrince4 @PeterMacCC #ASH20 #HodgkinsLymphoma #Cancer #Research The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study
    00:06:49

    Miles Prince, MD @MilesPrince4 @PeterMacCC #ASH20 #HodgkinsLymphoma #Cancer #Research The ECHELON-2 Trial: 5-year Results of a Randomized, Double-Blind, Phase 3 Study

    Free
    10 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Anna Sureda, MD, Ph.D. @AnnaSureda5 @bloodcellbcn #ASH20 #classicalhodgkinlymphoma #cancer #research 5-Year Update of the ECHELON-1 Study Anna Sureda, MD, Ph.D. @AnnaSureda5 @bloodcellbcn #ASH20 #classicalhodgkinlymphoma #cancer #research 5-Year Update of the ECHELON-1 Study
    00:15:05

    Anna Sureda, MD, Ph.D. @AnnaSureda5 @bloodcellbcn #ASH20 #classicalhodgkinlymphoma #cancer #research 5-Year Update of the ECHELON-1 Study

    Free
    21 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Mehul Dalal, Ph.D. @TakedaOncology #ASH20 #hodgkinslymphoma #cancer #research Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma Mehul Dalal, Ph.D. @TakedaOncology #ASH20 #hodgkinslymphoma #cancer #research Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma
    00:18:59

    Mehul Dalal, Ph.D. @TakedaOncology #ASH20 #hodgkinslymphoma #cancer #research Describing Treatment Pathways and Outcomes for Classical Hodgkin Lymphoma

    Free
    10 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    John Kuruvilla, MD @pmcancercentre @UofT #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research Randomized, Phase 3, Keynote-204 Study John Kuruvilla, MD @pmcancercentre @UofT #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research Randomized, Phase 3, Keynote-204 Study
    00:06:19

    John Kuruvilla, MD @pmcancercentre @UofT #ASH20 #ClassicalHodgkinLymphoma #Cancer #Research Randomized, Phase 3, Keynote-204 Study

    Free
    16 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    William G. Wierda, MD, Ph.D. @wwierda @MDAndersonNews #ASH20 #Lymphoma #CAPTIVATE #Cancer #Research The first presentation of disease-free survival results from the CAPTIVATE study William G. Wierda, MD, Ph.D. @wwierda @MDAndersonNews #ASH20 #Lymphoma #CAPTIVATE #Cancer #Research The first presentation of disease-free survival results from the CAPTIVATE study
    00:12:12

    William G. Wierda, MD, Ph.D. @wwierda @MDAndersonNews #ASH20 #Lymphoma #CAPTIVATE #Cancer #Research The first presentation of disease-free survival results from the CAPTIVATE study

    Free
    29 Views
    2 months ago
    ASHReport
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    John Kuruvilla, MD @pmcancercentre @UofT #classichodgkinlymphoma #cancer #research KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Adult Patients With Relapsed or Refractory cHL Afte... John Kuruvilla, MD @pmcancercentre @UofT #classichodgkinlymphoma #cancer #research KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Adult Patients With Relapsed or Refractory cHL Afte...
    00:05:46

    John Kuruvilla, MD @pmcancercentre @UofT #classichodgkinlymphoma #cancer #research KEYTRUDA Is the First Anti-PD-1 Therapy Approved for Adult Patients With Relapsed or Refractory cHL Afte...

    Free
    31 Views
    3 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Miguel Ferreira, MSc @globaldataplc #hodgkinslymphoma Hodgkin’s lymphoma market to suffer with Adcetris patent expiry but benefit from new competitive landscape, says GlobalData Miguel Ferreira, MSc @globaldataplc #hodgkinslymphoma Hodgkin’s lymphoma market to suffer with Adcetris patent expiry but benefit from new competitive landscape, says GlobalData
    0:11:28

    Miguel Ferreira, MSc @globaldataplc #hodgkinslymphoma Hodgkin’s lymphoma market to suffer with Adcetris patent expiry but benefit from new competitive landscape, says GlobalData

    Free
    197 Views
    5 months ago
    Cancer-News
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews
    0:06:48

    CAR T-cell therapy effective for relapsed/refractory MCL #ASH19 @michaelwangmd @MDAndersonNews

    Free
    338 Views
    1 year ago
    ash
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma
    00:19:35

    Practical Application of PET-Adapted Therapy in Hodgkin Lymphoma

    Free
    307 Views
    2 years ago
    MediComOncology
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    Promising therapeutic developments for Hodgkin lymphoma
    00:02:59

    Promising therapeutic developments for Hodgkin lymphoma

    Free
    149 Views
    2 years ago
    VJHemOnc
    Add to
    Want to watch this again later?
    Sign in to add this video to a playlist. Login
    • 1 (current)
    • 2
    • 3

    Copyright 2020 Medicus Networks, Inc. 27574 Commerce Center Drive, Suite 236, Temecula, CA 92592